Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00241722
Other study ID # 3753-013
Secondary ID SB-767905/014
Status Completed
Phase Phase 3
First received October 17, 2005
Last updated August 29, 2017
Start date August 1, 2005
Est. completion date February 1, 2007

Study information

Verified date August 2017
Source Cubist Pharmaceuticals LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Adults who are taking opioid therapy for persistent non-cancer pain and have resulting opioid-induced bowel dysfunction (OBD) will be randomized (1:1) to alvimopan or placebo. The primary objective of this Phase 3 long-term safety study is to compare alvimopan with placebo for safety and tolerability in the treatment of OBD. Participants will be required to attend 8 clinic visits over approximately 1 year.


Recruitment information / eligibility

Status Completed
Enrollment 805
Est. completion date February 1, 2007
Est. primary completion date February 1, 2007
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria:

- Consented to participate in this study.

- Taking opioid therapy for persistent non-cancer pain.

- Has bowel dysfunction mainly due to opioids.

- Has bowel dysfunction since starting opioids as defined by infrequent bowel movements and additional bowel-related symptoms.

- Willing to discontinue laxative therapy (will be provided study-specific standardized laxative if needed).

Exclusion criteria:

- Pregnant, lactating, or planning to become pregnant.

- Not ambulatory.

- Participated in another trial with an investigational drug in the past 30 days.

- Taking opioids for the management of drug addiction or cancer-related pain.

- Severe constipation whereby the subject is at immediate risk of developing serious complications of constipation.

- Gastrointestinal or pelvic disorders known to affect bowel transit, produce gastrointestinal (GI) obstruction, or contribute to bowel dysfunction.

- Human Immunodeficiency Virus (HIV)-infected, has active hepatitis, or has ever been infected with hepatitis C.

Study Design


Intervention

Drug:
Alvimopan

Placebo


Locations

Country Name City State
Australia GSK Investigational Site Bedford Park South Australia
Australia GSK Investigational Site Box Hill Victoria
Australia GSK Investigational Site Broadmeadow New South Wales
Australia GSK Investigational Site Carina Heights Queensland
Australia GSK Investigational Site Carlton Victoria
Australia GSK Investigational Site Fremantle Western Australia
Australia GSK Investigational Site Kippa Ring Queensland
Australia GSK Investigational Site Port Lincoln South Australia
Australia GSK Investigational Site St Leonards New South Wales
Australia GSK Investigational Site Toorak Gardens South Australia
Austria GSK Investigational Site Vienna
Austria GSK Investigational Site Vienna
Canada GSK Investigational Site Bonaventure Quebec
Canada GSK Investigational Site Brampton Ontario
Canada GSK Investigational Site Calgary Alberta
Canada GSK Investigational Site Chandler Quebec
Canada GSK Investigational Site Charlottetown Prince Edward Island
Canada GSK Investigational Site Coquitlam British Columbia
Canada GSK Investigational Site Drummondville Quebec
Canada GSK Investigational Site Edmonton Alberta
Canada GSK Investigational Site Halifax Nova Scotia
Canada GSK Investigational Site Hamilton Ontario
Canada GSK Investigational Site Kelowna British Columbia
Canada GSK Investigational Site Kitchener Ontario
Canada GSK Investigational Site Langley British Columbia
Canada GSK Investigational Site Mirabel Quebec
Canada GSK Investigational Site Mississauga Ontario
Canada GSK Investigational Site Moncton New Brunswick
Canada GSK Investigational Site Montreal Quebec
Canada GSK Investigational Site North Bay Ontario
Canada GSK Investigational Site North York Ontario
Canada GSK Investigational Site Saint John's Newfoundland and Labrador
Canada GSK Investigational Site Saint Romuald Quebec
Canada GSK Investigational Site Sherbrooke Quebec
Canada GSK Investigational Site Sudbury Ontario
Canada GSK Investigational Site Toronto Ontario
Canada GSK Investigational Site Toronto Ontario
Canada GSK Investigational Site Toronto Ontario
Canada GSK Investigational Site Toronto Ontario
Canada GSK Investigational Site Trois-Rivieres Quebec
Canada GSK Investigational Site Winnipeg Manitoba
Denmark GSK Investigational Site Ishoj
Finland GSK Investigational Site Helsinki
Hong Kong GSK Investigational Site Kowloon
Hong Kong GSK Investigational Site Kwun Tong
Hong Kong GSK Investigational Site Pokfulam
Hong Kong GSK Investigational Site Shatin
Hungary GSK Investigational Site Budapest
Ireland GSK Investigational Site Cork
Netherlands GSK Investigational Site Roosendaal
Netherlands GSK Investigational Site Utrecht
New Zealand GSK Investigational Site Christchurch
New Zealand GSK Investigational Site Hamilton
New Zealand GSK Investigational Site Tauranga
Poland GSK Investigational Site Gdansk
Poland GSK Investigational Site Krakow
Poland GSK Investigational Site Wroclaw
Spain GSK Investigational Site Alcorcon
Spain GSK Investigational Site Barcelona
Spain GSK Investigational Site El Ferrol
Spain GSK Investigational Site Granada
Spain GSK Investigational Site Madrid
Spain GSK Investigational Site Madrid
Spain GSK Investigational Site Santander
Spain GSK Investigational Site Valencia
Sweden GSK Investigational Site Jönköping
Sweden GSK Investigational Site Karlstad
Sweden GSK Investigational Site Linköping
Sweden GSK Investigational Site Stockholm
Switzerland GSK Investigational Site Bern
Taiwan GSK Investigational Site Tainan
Taiwan GSK Investigational Site Taipei
Taiwan GSK Investigational Site Taipei
United Kingdom GSK Investigational Site Bexhill-on-Sea, East Sussex
United Kingdom GSK Investigational Site Cardiff Glamorgan
United Kingdom GSK Investigational Site Coventry Warwickshire
United Kingdom GSK Investigational Site Glasgow Lanarkshire
United Kingdom GSK Investigational Site Glasgow Lanarkshire
United Kingdom GSK Investigational Site Leeds
United Kingdom GSK Investigational Site London
United Kingdom GSK Investigational Site Reading Berkshire
United Kingdom GSK Investigational Site Slough Berkshire
United Kingdom GSK Investigational Site Sunbury-on-Thames Middlesex
United Kingdom GSK Investigational Site Yaxley, Peterborough
United States GSK Investigational Site Albuquerque New Mexico
United States GSK Investigational Site Anaheim California
United States GSK Investigational Site Anaheim California
United States GSK Investigational Site Arlington Texas
United States GSK Investigational Site Arlington Heights Illinois
United States GSK Investigational Site Asheville North Carolina
United States GSK Investigational Site Bakersfield California
United States GSK Investigational Site Baton Rouge Louisiana
United States GSK Investigational Site Bellingham Washington
United States GSK Investigational Site Beverly Hills California
United States GSK Investigational Site Birmingham Alabama
United States GSK Investigational Site Birmingham Alabama
United States GSK Investigational Site Birmingham Alabama
United States GSK Investigational Site Blackwood New Jersey
United States GSK Investigational Site Bloomington Illinois
United States GSK Investigational Site Boise Idaho
United States GSK Investigational Site Boston Massachusetts
United States GSK Investigational Site Brandon Florida
United States GSK Investigational Site Brockton Massachusetts
United States GSK Investigational Site Brownwood Texas
United States GSK Investigational Site Buena Park California
United States GSK Investigational Site Burbank California
United States GSK Investigational Site Carnegie Pennsylvania
United States GSK Investigational Site Centerville Ohio
United States GSK Investigational Site Charleston West Virginia
United States GSK Investigational Site Charlotte North Carolina
United States GSK Investigational Site Chaska Minnesota
United States GSK Investigational Site Chattanooga Tennessee
United States GSK Investigational Site Chicago Illinois
United States GSK Investigational Site Chiefland Florida
United States GSK Investigational Site Cincinnati Ohio
United States GSK Investigational Site Cincinnati Ohio
United States GSK Investigational Site Clarksville Tennessee
United States GSK Investigational Site Clearwater Florida
United States GSK Investigational Site Clearwater Florida
United States GSK Investigational Site Clinton Oklahoma
United States GSK Investigational Site Columbus Ohio
United States GSK Investigational Site Concord North Carolina
United States GSK Investigational Site Dallas Texas
United States GSK Investigational Site Dawsonville Georgia
United States GSK Investigational Site Dayton Ohio
United States GSK Investigational Site Dayton Ohio
United States GSK Investigational Site Dayton Ohio
United States GSK Investigational Site Deerfield Beach Florida
United States GSK Investigational Site DeLand Florida
United States GSK Investigational Site Detroit Michigan
United States GSK Investigational Site Dover New Hampshire
United States GSK Investigational Site Edmonds Washington
United States GSK Investigational Site Elizabeth New Jersey
United States GSK Investigational Site Elkhart Indiana
United States GSK Investigational Site Fort Myers Florida
United States GSK Investigational Site Gainesville Florida
United States GSK Investigational Site Glendale Arizona
United States GSK Investigational Site Grand Blanc Michigan
United States GSK Investigational Site Grand Prairie Texas
United States GSK Investigational Site Greensboro North Carolina
United States GSK Investigational Site Greensboro North Carolina
United States GSK Investigational Site Henderson Nevada
United States GSK Investigational Site Hickory North Carolina
United States GSK Investigational Site Holly Hill Florida
United States GSK Investigational Site Hollywood Florida
United States GSK Investigational Site Hot Springs Arkansas
United States GSK Investigational Site Houston Texas
United States GSK Investigational Site Houston Texas
United States GSK Investigational Site Huntsville Alabama
United States GSK Investigational Site Indianapolis Indiana
United States GSK Investigational Site Jupiter Florida
United States GSK Investigational Site Kingsport Tennessee
United States GSK Investigational Site Lake Jackson Texas
United States GSK Investigational Site Lake Success New York
United States GSK Investigational Site Lancaster Texas
United States GSK Investigational Site Las Vegas Nevada
United States GSK Investigational Site Las Vegas Nevada
United States GSK Investigational Site Las Vegas Nevada
United States GSK Investigational Site Little Rock Arkansas
United States GSK Investigational Site Los Gatos California
United States GSK Investigational Site Louisville Kentucky
United States GSK Investigational Site Louisville Kentucky
United States GSK Investigational Site Madisonville Kentucky
United States GSK Investigational Site Manchester Missouri
United States GSK Investigational Site Marietta Georgia
United States GSK Investigational Site Medford Oregon
United States GSK Investigational Site Meridian Idaho
United States GSK Investigational Site Miami Florida
United States GSK Investigational Site Missoula Montana
United States GSK Investigational Site Mobile Alabama
United States GSK Investigational Site Muscle Shoals Alabama
United States GSK Investigational Site Nixa Missouri
United States GSK Investigational Site Norfolk Virginia
United States GSK Investigational Site Northport Alabama
United States GSK Investigational Site Ocala Florida
United States GSK Investigational Site Ocala Florida
United States GSK Investigational Site Oklahoma City Oklahoma
United States GSK Investigational Site Olive Branch Mississippi
United States GSK Investigational Site Omaha Nebraska
United States GSK Investigational Site Orange California
United States GSK Investigational Site Oregon City Oregon
United States GSK Investigational Site Orlando Florida
United States GSK Investigational Site Ormond Beach Florida
United States GSK Investigational Site Palm Springs California
United States GSK Investigational Site Pasadena Maryland
United States GSK Investigational Site Phoenix Arizona
United States GSK Investigational Site Phoenix Arizona
United States GSK Investigational Site Phoenix Arizona
United States GSK Investigational Site Pismo Beach California
United States GSK Investigational Site Pittsburgh Pennsylvania
United States GSK Investigational Site Portage Michigan
United States GSK Investigational Site Portland Oregon
United States GSK Investigational Site Raleigh North Carolina
United States GSK Investigational Site Reading Pennsylvania
United States GSK Investigational Site Richardson Texas
United States GSK Investigational Site Richmond Virginia
United States GSK Investigational Site Rockford Illinois
United States GSK Investigational Site Rockville Maryland
United States GSK Investigational Site Saint Cloud Florida
United States GSK Investigational Site Saint Louis Missouri
United States GSK Investigational Site Salt Lake City Utah
United States GSK Investigational Site Salt Lake City Utah
United States GSK Investigational Site San Antonio Texas
United States GSK Investigational Site San Diego California
United States GSK Investigational Site San Diego California
United States GSK Investigational Site San Diego California
United States GSK Investigational Site Scottsdale Arizona
United States GSK Investigational Site Scottsdale Arizona
United States GSK Investigational Site Shreveport Louisiana
United States GSK Investigational Site Spokane Washington
United States GSK Investigational Site Stockbridge Georgia
United States GSK Investigational Site Stratford Connecticut
United States GSK Investigational Site Sun City Arizona
United States GSK Investigational Site Suwanee Georgia
United States GSK Investigational Site Tacoma Washington
United States GSK Investigational Site Tempe Arizona
United States GSK Investigational Site Torrance California
United States GSK Investigational Site Traverse City Michigan
United States GSK Investigational Site Trumbull Connecticut
United States GSK Investigational Site Tucson Arizona
United States GSK Investigational Site Tucson Arizona
United States GSK Investigational Site Virginia Beach Virginia
United States GSK Investigational Site Vista California
United States GSK Investigational Site Wellesley Hills Massachusetts
United States GSK Investigational Site West Palm Beach Florida
United States GSK Investigational Site Winston-Salem North Carolina
United States GSK Investigational Site Woonsocket Rhode Island

Sponsors (2)

Lead Sponsor Collaborator
Cubist Pharmaceuticals LLC GlaxoSmithKline

Countries where clinical trial is conducted

United States,  Australia,  Austria,  Canada,  Denmark,  Finland,  Hong Kong,  Hungary,  Ireland,  Netherlands,  New Zealand,  Poland,  Spain,  Sweden,  Switzerland,  Taiwan,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary To compare alvimopan with placebo for long-term safety and tolerability 12 months
Secondary Quality of life, pharmacokinetics, pharmacogenetics (dependent on results from other data) 12 months
See also
  Status Clinical Trial Phase
Completed NCT05517460 - The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center N/A
Recruiting NCT06292949 - Clinical Study of Resistant Starch in Improving Constipation N/A
Recruiting NCT04132661 - MRI Assessment of Mode of Action of Bisacodyl, Single Dose Phase 4
Completed NCT02726295 - The Efficacy of Mutaflor(E. Coli Nissle 1917, Mutaflor®) for Chronic Constipation:Multicenter Study Phase 4
Terminated NCT02839889 - Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation) Phase 4
Recruiting NCT02255747 - Anal Dilatation for Infants and Children With Constipation N/A
Completed NCT02246647 - Biomarkers for Intestinal Permeability in Patients With Constipation
Completed NCT01566409 - Maintenance Treatment for Children With Constipation N/A
Completed NCT02863848 - Effect of Inulin-type Fructans on Constipated Children. N/A
Completed NCT01695915 - Diurnal Variation in Rectal Diameter N/A
Completed NCT02658201 - Ultrafast MRI Imaging to Exclude Constipation N/A
Completed NCT01710579 - Normal Values in Ano-rectal 3D High Resolution Manometry N/A
Completed NCT01438567 - A Study to Demonstrate Improvement in Symptoms of Constipation in Subjects That Require Around-the-clock Opioid Pain Killer Therapy Phase 3
Completed NCT01411501 - Efficacy and Safety of Acupuncture for Functional Constipation Phase 3
Completed NCT01474499 - A Trial of Docusate Sodium and Sorbitol Rectal Solution for the in Patients With Constipation Phase 3
Completed NCT01170039 - The Effectiveness of Lubiprostone in Constipated Diabetics Phase 4
Completed NCT00931853 - Efficacy and Tolerability of Cassia Fistula Plus Senna Alexandrina Miller (Sugar Free) in the Chronic Functional Constipation (CFC). Phase 3
Active, not recruiting NCT02442115 - Impact of Improving GI Symptoms on Autism Symptoms and Oxidative Stress
Completed NCT00994851 - Evaluation of Cassia Fistula + Senna Alexandrina Miller in the Chronic Functional Constipation Treatment. Phase 3
Terminated NCT01003249 - Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen Phase 4